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Introduction {#sec1-1}
============

The consensus for treating infants with obstetric brachial plexus palsy is that nerve reconstruction surgery of the lower trunk should be performed up to 3 months postnatally (Chuang et al., 2005). For upper trunk injuries, the operation may be performed at 30 months or later (Boome et al., 2000). In a rat model of obstetric brachial plexus palsy, denervated intrinsic musculature of the forepaw (IMF) and denervated biceps had different histological features at different time points. We confirmed that it took a much shorter time for atrophy of denervated IMF to become irreversible compared with denervated biceps. This may be a key explanation for the more limited timing required for nerve reconstruction surgery of the lower trunk in obstetric brachial plexus palsy (Wu et al., 2013). In another study using a rat obstetric brachial plexus palsy model in which IMF atrophy was irreversible but that of the biceps remained reversible at 5 weeks after denervation, it was found that miRNA expression differed between the two denervated muscles. Moreover, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, as well as mapping of specifically dysregulated miRNAs and target genes, suggested that most affected pathways were involved in self-regulation of neuromuscular junctions (Pan et al., 2015). A further study emplying the same model showed that mRNA expression profiles in denervated IMF were lacking in genes mapping to pathways of muscular regrowth and differentiation compared with patterns in denervated biceps (Wu et al., 2016), indicating that insufficient levels of self-protective factors were one reason that the atrophic process of denervated IMF occurred more rapidly than in denervated biceps. However, these results provided little evidence for the involvement of inflammation and apoptosis in IMF, although these processes are considered to be critical for modulating atrophic processes in denervated muscles (Tidball et al., 2005).

After denervation, loss of muscle contraction leads to blood accumulation in the venous system, which induces leukocyte transmigration (Pober et al., 1990), aseptic inflammation (Iversen et al., 2005), and muscle cell apoptosis (Rowe et al., 2000). Theoretically, denervated IMF incurs more severe inflammation than denervated biceps because venous return is more hindered by gravity in the former. In our mRNA profiling study of the obstetric brachial plexus palsy model, only the p53 signaling pathway, which is associated with inflammation and muscle cell apoptosis, was upregulated in denervated IMF compared with the contralateral normal control (Wu et al., 2016). Based on reports that skeletal muscle inflammation occurred as early as 10 hours after nerve sectioning (Levine et al., 1990) and is preceded by onset of muscle cell proliferation (Murray et al., 1982), we believe that by sampling at 5 weeks after denervation, we missed peak expression of inflammation and apoptosis signaling in IMF. As atrophy becomes irreversible much sooner in denervated intrinsic muscles of the hand, we hypothesized that protein expression characteristics would differ between denervated IMF and biceps, with the former having more upregulated signaling related to inflammation and apoptosis than its contralateral counterpart. This study, therefore, aimed to test that hypothesis by dynamically analyzing protein expression profiles in denervated IMF and biceps.

Materials and Methods {#sec1-2}
=====================

Animal surgery and sample preparation {#sec2-1}
-------------------------------------

A total of 120 Sprague-Dawley rats were obtained at 7 days after birth from the Experimental Animal Science Department, Fudan University, China (license number: SYXK (Hu) 2014-0029). This study was approved by the Experimental Animal Ethics Committee of Fudan University, China (approval No. DF-325) in January 2015. After intraperitoneal injection of 10% chloral hydrate (300 mg/kg), each rat was placed in a supine position and the right brachial plexus was exposed through the supraclavicular route.

C5--C6 spinal nerves were lacerated and C7--C8--T1 were avulsed. After 3 weeks, 60 rats were sacrificed and samples of denervated IMF and biceps on the right side and their normal counterparts on the left side were harvested. Of these, samples from 40 rats were labeled with isobaric tags for relative and absolute quantitation (iTRAQ). Samples from the remaining 20 rats were analyzed by western blot assay to verify iTRAQ results. At 5 weeks after surgery, samples were obtained from the other 60 rats using the same procedures. To prepare samples for iTRAQ, muscles were frozen in liquid nitrogen and ground with a mortar and pestle. Next, buffer (4% sodium dodecyl sulfate and 0.1 M dithiothreitol in 0.1 M Tris-HCl, pH 7.6) was added to each sample and the resulting lysates were sonicated and boiled for 15 minutes. After centrifugation, protein levels were measured in supernatants with a bicinchoninic acid protein assay kit (Bio-Rad, Hercules, CA, USA). Protein solutions from denervated IMF were pooled, as were those from denervated biceps. Samples on the contralateral side were prepared using the same procedures. All mixtures of protein solutions were pre-processed by filter-aided sample preparation digestion. Protein suspensions were digested with 4 µg trypsin (Promega Biotech, Beijing, China) in 40 µL of dissolution buffer (SCIEX, Shanghai, China) overnight and the resulting peptides were collected as a filtrate. Peptides within each combined solution were desalted on C18 Cartridges (Empore™ SPE; Minnesota Mining and Manufacturing Company, St. Paul, MN, USA) and stored at --80°C.

iTRAQ labeling and LC-MS/MS analysis {#sec2-2}
------------------------------------

iTRAQ was carried out at 3 and 5 weeks to examine prepared samples. According to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA), 100 µg of peptide mixture from each sample was labeled with iTRAQ reagents as follows: control IMF by 114 tag, denervated IMF by 115 tag, control biceps by 116 tag, and denervated biceps by 117 tag. Labeled peptides were fractionated by strong cation exchange chromatography using an AKTA Purifier system (GE Healthcare, Shanghai, China) and then desalted on C18 Cartridges. Samples were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS). EASY-nLC™, a high-performance liquid chromatography system, was used to separate each fraction, which was then analyzed on a Q-Exactive mass spectrometer (Thermo Fisher Scientific, Shanghai, China) in positive ion mode. The resolution of survey scans was set to 70,000 at 200 m/z, while that of high-energy collisional dissociation spectra scans was set to 17,500 at 200 m/z. Information-dependent acquisition was enabled with automatic collision energy.

Protein identification and quantitation {#sec2-3}
---------------------------------------

Protein identification was performed on each result of iTRAQ. LC-MS/MS spectra were searched using the MASCOT search engine (Matrix Science, UK; version 2.3) embedded into Proteome Discoverer 1.4 (Thermo Fisher Scientific, 2012). For protein identification, search parameters were as follows: maximum missed cleavages = 2, enzyme = trypsin, peptide mass tolerance = ± 20 ppm, and fragmented mass tolerance = 0.1 Da. Weighed and standardized quantitative protein ratios were determined between denervated IMF and control samples, and between denervated biceps and control samples. Only proteins with a fold change ≥ 1.5 and *P*-value \< 0.05 were considered dysregulated. Differential expression of proteins was then depicted in volcano plots according to fold changes and *P*-values. Names of dysregulated proteins were designated using the format of UniProt Knowledgebase (<https://www.uniprot.org>).

Bioinformatics {#sec2-4}
--------------

KEGG database analysis (<https://www.kegg.jp/>) was applied to determine enriched pathways for dysregulated proteins identified in denervated IMF and biceps at 3 and 5 weeks. To identify the significance of pathways, either Fisher's exact or chi-square test was used to calculate *P*-values. Only KEGG pathways with *P*-values \< 0.05 were considered significant.

Western blot assay {#sec2-5}
------------------

For IMF and biceps on both denervated and contralateral sides, 20 sets of samples were harvested at 3 weeks and 20 sets were collected at 5 weeks. Cytochrome c oxidase subunit 6C (COX6C) and myosin heavy chain 1 (MYH1) were randomly chosen for western blot assay to validate iTRAQ results. Radioimmunoprecipitation assay buffer was used to pre-process each tissue. Aliquots of 60 µg protein from each sample were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to membranes; glyceraldehyde-phosphate dehydrogenase (GAPDH) was used as the internal reference. Membranes were incubated with primary goat anti-rat polyclonal antibodies of COX6C or MYH1 respectively (1:1000; Goodbio Technology, Wuhan, China) overnight at 4°C and then with a horseradish peroxidase-conjugated donkey anti-goat secondary antibody (1:3000; Goodbio Technology) at room temperature for 30 minutes. An ECL detection system (Amersham Biosciences, Buckinghamshire, UK) was used to visualize stained bands, which were quantified by grayscale value ratios to the internal reference using AlphaEaseFC software (Alpha Innotech, San Leandro, CA, USA).

Statistical analysis {#sec2-6}
--------------------

Data are expressed as ratios of grayscale values relative to internal controls. Statistical analysis was performed with SPSS 19.0 software (IBM, Armonk, NY, USA). A random variance model *t* test was used to test the distribution and identify dysregulated proteins by comparing protein expression in denervated muscles with their respective controls. For western blot assay, an independent two-tailed *t* test was used to compare results for each protein in denervated muscles with those in corresponding control muscles on the contralateral side. *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

Proteomics and bioinformatics {#sec2-7}
-----------------------------

iTRAQ results are shown in **[Figure 1](#F1){ref-type="fig"}**. Compared with contralateral tissue, 845 dysregulated proteins were identified in denervated IMF at 3 weeks (**[Figure 1A](#F1){ref-type="fig"}**), including 323 that were mapped to 60 pathways by KEGG analysis. Among KEGG database pathways related to muscle and nerve, 119 dysregulated proteins were mapped to nine pathways. Of those, five pathways with 27 upregulated proteins were related to inflammation and apoptosis, including cGMP-PKG, MAPK signaling, insulin, pyruvate metabolism, and HIF-1 pathways. The other four pathways, to which 98 downregulated proteins were mapped, were associated with regrowth and differentiation, including calcium signaling, tight junction, AMPK signaling, and fatty acid metabolism (**[Table 1](#T1){ref-type="table"}**). At 5 weeks, 448 dysregulated proteins were identified (**[Figure 1C](#F1){ref-type="fig"}**), of which 225 were mapped to 20 pathways. There were 67 dysregulated proteins that mapped to three pathways connected to nerve and muscle, including: pyruvate metabolism with one upregulated protein related to apoptosis, calcium signaling with 25 downregulated proteins related to differentiation, and glycolysis/gluconeogenesis with 27 downregulated proteins associated with energy metabolism in muscle cells (**[Table 1](#T1){ref-type="table"}**).

![Volcano plots of protein expression ratios in denervated IMF and biceps at 3 and 5 weeks compared with respective contralateral controls.\
(A--D) Volcano plots showing all proteins detected by iTRAQ in denervated IMF (A, C) and denervated biceps (B, D) at 3 (A, B) and 5 (C, D) weeks compared with corresponding muscles on the contralateral side. Pink dots represent proteins whose upregulation or downregulation was both statistically significant (*P* \< 0.05) and 1.5-fold or more different from those in muscle on the contralateral side. Black dots indicate proteins whose dysregulation was either not statistically significant or had a statistical difference less than 1.5-fold relative to corresponding proteins on the contralateral side. IMF: Intrinsic musculature of the forepaw .](NRR-15-1326-g002){#F1}

###### 

KEGG pathways, to which both upregulated and downregulated proteins in denervated IMF were mapped, at 3 and 5 weeks after denervation

  Term                         Count^a^   Protein name^b^                                                                                                                                                                                                                                                      *P*-value
  ---------------------------- ---------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  Pathways at 3 weeks                                                                                                                                                                                                                                                                                          
  cGMP-PKG pathway             21         F1LV12^\*^, Q3HSE5^\*^, P16067^\*^, P63329, Q64578, P62142, P13638, B3XZL8, P07340, A0A0H2UHV6, G3V6V5, P06686, P61589, G3V731, P81155, Q9Z2L0, Q05962, D3ZB81, A0A0G2JSR0, P29117, Q64595                                                                           0.001
  MAPK signaling               26         Q5BJU0^\*^, D3Z8L7^\*^, Q3HSE5^\*^, Q62862^\*^, G3V6P8^\*^, B5DFH7^\*^, Q6MGC8^\*^, A0A0H2UHR7, D4AE17, P63329, P14659, P0DMW0, D3Z8E0, B1H230, G3V913, B3XZL8, Q925D6, A0A0H2UHV6, Q4G050, Q63538, Q6P727, A0A0G2K4U4, P53042, Q66H84, G3V6E5, F1LXV0               0.001
  Insulin pathway              20         P12785^\*^, A0A0G2K5G8^\*^, Q3HSE5^\*^, P12369^\*^, G3V8R5^\*^, Q9Z2S9^\*^, P19357, M0RD75, D3ZM60, P13286, P27881, P62142, F1LLZ7, A2RRU1, P97531, G3V8V3, Q4G050, A0A0G2K9C8, Q6P727, Q9Z1N1                                                                       0.002
  Pyruvate metabolism          17         A0A0G2K5G8^\*^, P52873^\*^, Q6P7Q4, P11980, P04636, A0A0G2K4C6, P35745, F7FKI5, P17764, O88989, P42123, P08461, P14408, Q6P6R2, A0A0G2JZH8, P49432, B0BN46                                                                                                           \< 0.001
  HIF-1 pathway                14         Q3HSE5^\*^, Q9ET45^\*^, P15429, M0RD75, A0A0G2K7M1, P27881, P07323, M0R660, Q4G050, F7FKI5, P49432, E9PTN6, P11275, G3V679, E9PTV9                                                                                                                                   0.006
  Calcium pathway              22         F1LV12^\*^, F1LMY4, P63329, Q304F3, Q64578, P13286, A0A0G2K5J1, F1LPJ2, Q4PP99, B3XZL8, F1LLZ7, A0A0H2UHV6, G3V731, P81155, A0A0G2K9C8, Q9Z2L0, Q05962, D3ZB81, A0A0G2JSR0, P29117, P11275, Q62711, F1LQL1                                                           \< 0.001
  Tight junction               20         Q5BJU0^\*^, A0A0G2JUX7^\*^, D3Z8L7^\*^, Q3HSE5^\*^, D4AE17, P04466, A0A0G2JSQ0, A0A0G2K484, F1LRV9, D3ZCV0, P61589, G3V6E1, Q6GMN8, Q8K551, A0A0G2JYA4, Q29RW1, P62716, A0A0G2KA61, B1WC41, F1M4I1                                                                   0.003
  AMPK signaling               16         P12785^\*^, A0A0G2K5G8^\*^, Q3HSE5^\*^, G3V8R5^\*^, P19357, A0A0G2JSQ0, Q52KS1, A2RRU1, Q5XIJ7, Q5PQN8, D4AC16, A0A0G2JYA4, Q9Z1N1, P62716, C9DRP4, Q63704                                                                                                           0.005
  Fatty acid metabolism        12         P12785^\*^, A0A0G2K5G8^\*^, Q63151^\*^, P33124, P17764, Q9WVK7, Q9WVK3, P08503, P70584, P14604, Q5M9H2, Q63704                                                                                                                                                       0.002
  Pathways at 5 weeks                                                                                                                                                                                                                                                                                          
  Glycolysis/gluconeogenesis   29         G3V9W6^\*^, P25113^\*^, D3ZZN3, P07323, P30835, A0A0G2JZH8, Q6P9U7, E9PTN6, D4A5G8, Q9Z1N1, B1WBN9, P49432, E9PTV9, Q6P6R2, P08461, P27881, P09117, P16617, P42123, P48500, Q6P6G4, Q6P6V0, Q499Q4, M0R660, P16290, P15429, P11980, Q52KS1, P05065                   \< 0.001
  Calcium signaling            29         G3V6Q6^\*^, D3ZH00^\*^, P15791^\*^, Q09073^\*^, P29117, P68182, D3ZB81, A0A0G2K5J1, P84903, A0A0G2JSR0, F1LMY4, Q4PP99, P13286, P81155, G3V9D1, G3V731, P11275, P20651, P63329, A0A0G2K9C8, A1L1M0, P10688, F1LLZ7, Q05962, Q9Z2L0, B3XZL8, F1LPJ2, Q304F3, Q64578   \< 0.001
  Pyruvate metabolism          20         G3V9W6^\*^, D3ZJH9, D3ZZN3, A0A0G2K4C6, A0A0G2JZH8, Q6P9U7, D4A5G8, B1WBN9, P17764, P49432, P35745, Q6P6R2, P08461, B0BN46, P14408, P42123, O88989, Q6P7Q4, P04636, P11980                                                                                           \< 0.001

^a^Expression of proteins was compared between denervated IMF and normal IMF, the latter on the contralateral side. ^a^This refers to the quantity of upregulated and downregulated proteins mapping to the pathway. ^b^Protein name is shown in the format of the UniProt Knowledgebase. ^\*^Upregulated proteins in denervated IMF. No asterisk means downregulated proteins in denervated IMF.

Compared with the contralateral tissue, 592 dysregulated proteins were identified in denervated biceps at 3 weeks (**[Figure 1B](#F1){ref-type="fig"}**), including 323 that were mapped to 35 KEGG pathways. Of these, 64 dysregulated proteins were mapped to five pathways related to muscle and nerve according to the KEGG database, including: pyruvate metabolism with one upregulated protein related to apoptosis; calcium signaling, fatty acid metabolism, and PPAR signaling with four upregulated proteins associated with regrowth and differentiation; and glycolysis/gluconeogenesis, which is related to muscle cell energy metabolism (**[Table 2](#T2){ref-type="table"}**) At 5 weeks, 44 dysregulated proteins were identified (**[Figure 1D](#F1){ref-type="fig"}**), of which 32 were mapped to eight KEGG pathways. Five dysregulated proteins were mapped to three pathways related to muscle and nerve. Among these, taurine and hypotaurine metabolism, and pyruvate metabolism, which had three downregulated proteins, were related to apoptosis and fatty acid metabolism, while the other two downregulated proteins were associated with proliferation (**[Table 2](#T2){ref-type="table"}**).

###### 

KEGG pathways, to which both upregulated and downregulated proteins in the denervated biceps were mapped, at 3 and 5 weeks after denervation

  Term                                 Count^a^   Protein name^b^                                                                                                                                                                                              *P*-value
  ------------------------------------ ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------
  Pathways at 3 weeks                                                                                                                                                                                                                                          
  Glycolysis / Gluconeogenesis         22         P11884^\*^, P07323, E9PTV9, P16617, P04642, P48500, P11980, P16290, P15429, Q52KS1, Q6P6V0, A0A0G2K7M1, E9PTN6, M0R660, Q9Z1N1, P05065, Q6P6R2, P08461, D3ZZN3, F7FKI5, P49432, A0A0G2JZH8                   \< 0.001
  Pyruvate metabolism                  17         P11884^\*^, B0BN46, P04642, P11980, P35745, P14408, A0A0G2K4C6, Q6P6R2, P04636, P08461, D3ZZN3, F7FKI5, P49432, P17764, A0A0G2JZH8, A0A0G2K1W9, O88989                                                       \< 0.001
  Fatty acid metabolism                18         O35547^\*^, Q63151^\*^, P70584, Q9WVK3, P33124, G3V9U2, P14604, P17764, P15651, Q64428, Q5M9H2, Q9WVK7, Q60587, P18163, P18886, P08503, P07896, G3V7N5                                                       \< 0.001
  Calcium signaling                    16         P11275, P20651, A0A0G2K9C8, P13286, Q64578, A0A0G2JSR0, F1LLZ7, Q304F3, G3V731, A0A0G2K5J1, F1LQL1, P29117, Q9Z2L0, Q05962, Q62711, D3ZB81                                                                   \< 0.001
  PPAR signaling                       9          O35547^\*^, Q63151^\*^, P33124, M0R7S5, P18163, P18886, P08503, P07896, G3V7N5                                                                                                                               0.008
  Pathways at 5 weeks                             F1LV12^\*^, F1LMY4, P63329, Q304F3, Q64578, P13286, A0A0G2K5J1, F1LPJ2, Q4PP99, B3XZL8, F1LLZ7, A0A0H2UHV6, G3V731, P81155, A0A0G2K9C8, Q9Z2L0, Q05962, D3ZB81, A0A0G2JSR0, P29117, P11275, Q62711, F1LQL1   \< 0.001
  Taurine and hypotaurine metabolism   2          Q5PQV0^\*^, A0A0G2K5P7                                                                                                                                                                                       \< 0.001
  Fatty acid metabolism                2          A0A0G2K5G8, P12785                                                                                                                                                                                           0.036
  Pyruvate metabolism                  2          A0A0G2K5G8, P13697                                                                                                                                                                                           0.039

Expression of proteins was compared between the denervated biceps and the normal biceps, the latter on the contralateral side. ^a^This refers to the number of upregulated and downregulated proteins mapping to the pathway. ^b^Protein name is shown in the format of the UniProt Knowledgebase. ^\*^Upregulated proteins in the denervated biceps. No asterisk means downregulated proteins in the denervated biceps.

Validation by western blot assay {#sec2-8}
--------------------------------

Two proteins, cytochrome c oxidase subunit 6C (COX6C) and myosin heavy chain 1 (MYH1), were randomly selected from dysregulated proteins in denervated IMF and biceps for analysis by western blot assay to validate iTRAQ results. Based on densitometric values compared with the internal reference, MYH1 and COX6C were downregulated in both denervated IMF and denervated biceps compared with corresponding tissue on the contralateral side at 3 weeks (*P* \< 0.05; **[Figure 2A](#F2){ref-type="fig"}**). At 5 weeks, these two proteins were downregulated in denervated IMF, but upregulated in denervated biceps (*P* \< 0.05; **[Figure 2B](#F2){ref-type="fig"}**). These results were consistent with those obtained by iTRAQ.

![Validation of decreased MYH1 and COX6C protein levels at 3 and 5 weeks by western blot assay.\
(A) Levels of MYH1 and COX6C proteins were decreased in denervated intrinsic musculature of the forepaw (IMF) and biceps compared with in biceps on the contralateral side at 3 weeks (\**P* \< 0.05). (B) Levels of MYH1 and COX6C proteins were decreased in denervated IMF, but increased in the denervated biceps, compared with corresponding muscles on the contralateral side at 5 weeks (\**P* \< 0.05). Representative western blot assay results are shown on the left, while ratios of grayscale values compared with the internal control are shown in the right. Verified proteins are indicated along the X-axis, while the Y-axis indicates the ratio of grayscale values between targeted protein and an internal reference. All results were consistent with data from iTRAQ.](NRR-15-1326-g003){#F2}

Discussion {#sec1-4}
==========

One of the primary reasons for failure of nerve repair is that muscle atrophy can become irreversible before regenerating nerves can reinnervate target muscles (Roganovic et al., 2005; Piras and Boido, 2018; Weng et al., 2018; Zhang et al., 2018). Using the obstetric brachial plexus palsy rat model, whereby atrophy of denervated IMF is irreversible but that of denervated biceps is reversible, our previous study showed that IMF and biceps had distinct miRNA expression patterns after denervation. In a subsequent study of mRNA profiles, pathways associated with muscular regrowth and differentiation were more active in denervated biceps than in denervated IMF. In the present study examining the same model at 3 weeks after denervation, nine pathways in IMF were identified by KEGG analysis and five of these were related to inflammation and apoptosis. The MAPK pathway, to which upregulated Ras-related protein and mitogen-activated protein kinase 5 were mapped in this study, reportedly recruited leukocytes and evoked inflammatory cascades during inflammation in denervated skeletal muscle (Li et al., 2005). HIF-1 signaling, for which BCL2/adenovirus E1B 19-kDa protein-interacting protein 3 was upregulated in this study, was previously shown to be activated during muscle injury (Taylor et al., 2008). The pyruvate metabolism pathway, to which downregulated pyruvate kinase and malate dehydrogenase were mapped, can inhibit apoptosis induced by free radicals (Kang et al., 2001). The cGMP-PKG pathway, to which downregulated cGMP-dependent protein kinase 2 was mapped, can reportedly mediate vasodilation and chemotaxis during inflammation (Browner et al., 2004). The insulin pathway, for which phosphorylase b kinase and 40S ribosomal protein were upregulated, was shown to inhibit migration of inflammatory cells into skeletal muscle (Wei et al., 2008). The remaining four activated pathways were related to regrowth and differentiation. Among these, the tight junction pathway (Röder et al., 2008), to which upregulated Ras-related protein and membrane-associated guanylate kinase were mapped in this study, and calcium signaling with downregulated calcium/calmodulin-dependent protein was mapped in a previous study (Wu et al., 2000), can enhance regeneration of muscle cells. In contrast, AMPK signaling (Motoshima et al., 2006) and the fatty acid metabolism pathway (Bonen et al., 1999), both with upregulated fatty acid synthase and cetyl-CoA carboxylase, can restrict regrowth of muscle cells. At 5 weeks, three pathways with dysregulated proteins were identified in denervated IMF: pyruvate metabolism with downregulated pyruvate kinase, calcium signaling with downregulated calcium/calmodulin-dependent protein, and glycolysis/gluconeogenesis with downregulated 6-phosphofructokinase, which can enhance energy metabolism in muscle cells (Kelley et al., 1988). These results suggest that in denervated IMF, peak inflammation and apoptosis occur earlier than 5 weeks after denervation, while signaling for regrowth and differentiation was stably expressed at low levels. As inflammation and apoptosis proceeded, the muscle structure was substantially damaged such that denervated IMF was deprived of its self-regulating ability, irreversibly becoming atrophic.

At 3 weeks in denervated biceps, upregulated and downregulated proteins were mapped to five pathways related to nerve and muscle including: pyruvate metabolism with downregulated pyruvate kinase, calcium signaling with downregulated adenylate cyclase type 2, fatty acid metabolism with upregulated fatty acid synthase and long chain fatty CoA ligase 2, glycolysis/gluconeogenesis with downregulated 6-phosphofructokinase, and PPAR signaling with upregulated long chain fatty acid CoA ligase 3. Notably, the PPAR signaling pathway can function in repair of denervated neuromuscular junctions (Da Cruz et al., 2012). At 5 weeks, five proteins that mapped to three pathways involving muscle and nerve were dysregulated. Of these, downregulated acetyl-CoA carboxylase was associated with pyruvate metabolism and upregulated gamma-glutamyltransferase 5 was related to taurine and hypotaurine metabolism, which can reportedly inhibit inflammation (Das et al., 2012). The third identified pathway, fatty acid metabolism, was the only pathway related to muscle cell regrowth and differentiation to which downregulated fatty acid synthase was mapped. In our previous study, mRNA microarray analysis of the same muscles at 5 weeks mapped upregulated mRNAs to five signaling pathways relevant to the promotion of muscle cell regrowth and differentiation (Wu et al., 2016). Possible reasons for identifying fewer pathways related to regrowth and differentiation at 5 weeks in this proteomic study include half-life differences (Maier et al., 2009) and variations in post-translational modifications among identified proteins (Greenbaum et al., 2003). Regardless, our proteomic results comparing denervated biceps with its normal counterpart indicate that signaling for inflammation and apoptosis was inactive both at 3 and 5 weeks, suggesting that inflammation and apoptosis had not substantially damaged the structure of the denervated biceps at 5 weeks, such that its capacity for self-regulation was maintained and muscle atrophy remained reversible.

Denervation can lead to the onset of inflammation by stimulating neutrophil infiltration (Levine et al., 1990), and can also induce muscle apoptosis (Always et al., 2003). Our proteomic results suggest that after denervation, processes of inflammation and apoptosis in IMF were more intense than in biceps, at least at earlier time points. There are several potential reasons for this difference. First, coordinated and fine motor activities of the hand begin 10--12 months after birth (Schieber et al., 2004), while the embrace reflex, which is related to contraction of the biceps, appears prenatally (Zafeiriou et al., 2004). This suggests that intrinsic muscles of the hand mature later than the biceps, leaving them more vulnerable to inflammation and apoptosis. Second, muscles controlling fine motor activities, such as facial and pharyngeal muscles, were clinically observed to be more susceptible to immune attack than limb muscles in myasthenia gravis (Evoli et al., 2003). Therefore, we speculated that intrinsic muscles in the hand, which manage complex and fine motor movements, are also more vulnerable than biceps to damage caused by denervation. Third, as intrinsic muscles of the hand are further from the heart than biceps, return of venous blood to the former is more hindered by gravity than flow to the latter. Indeed, because of greater venous congestion in denervated intrinsic muscles of the hand, the extent of inflammation may be more severe compared with denervated biceps. Based on the results of our proteomic analysis, which is just a macro analysis, we predicted potential causes underlying the different processes of irreversible muscle atrophy in intrinsic muscles of the hand and biceps. Therefore, more detailed experiments are needed to further validate the results.

In the rat model of obstetric brachial plexus palsy, whereby atrophy of IMF is irreversible but that of the biceps is reversible, our proteomic analysis suggested that pathways related to inflammation and apoptosis were clearly activated at 3 weeks, but significantly decreased at 5 weeks in denervated IMF; whereas, these pathways remained inactive both at 3 and 5 weeks in denervated biceps. This indicates that more significant inflammation and apoptosis in intrinsic muscles of the hand after denervation may be a major reason why atrophy of these muscles becomes irreversible faster than in denervated biceps.
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